MXCT MaxCyte, Inc.

NASDAQ
$1.25

MaxCyte, Inc. (MXCT) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -10.7% since its last earnings release on November 10, 2026.

MaxCyte Beat Consensus Estimates, Raises Guidance
Tuesday, November 10, 2026 · 6:01 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.06)
Rev est $7.4M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.16

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MaxCyte, Inc.

MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.